Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

Table 3 Comparison of the secondary end-points

	Before treatment			After treatment
	UTI group (n = 91)	Placebo group (n = 90)	P value	UTI group (n = 91)	Placebo group (n = 90)	P value
Inflammatory cytokine, mean ± SD
TNF-α (pg/mL)	77.28 ± 19.43	76.91 ± 18.27	0.895	29.67 ± 11.19	43.17 ± 12.08	< 0.001
IL-6 (pg/mL)	89.37 ± 16.28	87.91 ± 16.74	0.553	50.18 ± 12.24	66.35 ± 14.26	< 0.001
Coagulation function, mean ± SD
PT (s)	21.05 ± 3.44	20.62 ± 3.19	0.385	12.16 ± 2.84	16.71 ± 3.15	< 0.001
APTT (s)	39.22 ± 4.26	40.15 ± 4.39	0.150	32.26 ± 3.73	37.25 ± 4.02	< 0.001
D-D (mg/L)	4.26 ± 1.12	4.33 ± 1.27	0.694	1.75 ± 0.59	2.94 ± 0.79	< 0.001
FIB (g/L)	1.07 ± 0.23	1.12 ± 0.26	0.172	3.46 ± 0.60	3.28 ± 0.55	0.037
Infection index levels, mean ± SD
CRP (mg/L)	31.29 ± 4.16	30.98 ± 4.07	0.613	5.19 ± 0.97	8.34 ± 1.33	< 0.001
PCT (ng/L)	2.05 ± 0.21	2.10± 0.19	0.095	0.75 ± 0.23	0.82 ± 0.38	0.135
WBC (× 109/L)	18.05 ± 9.11	17.56 ± 8.97	0.716	12.74 ± 6.41	15.19 ± 7.29	0.017
Liver function index levels, mean ± SD
ALT (U/L)	32.20 ± 3.74	33.15 ± 3.68	0.087	48.19 ± 4.27	53.11 ± 4.53	< 0.001
AST (U/L)	34.17 ± 2.83	34.42 ± 2.99	0.564	49.67 ± 3.88	50.27 ± 4.19	0.230
Renal function index levels, mean ± SD
Scr	81.26 ± 9.91	79.64 ± 9.12	0.254	84.22 ± 10.16	105.42 ± 11.20	< 0.001
BUN	5.37 ± 1.94	5.19 ± 1.73	0.511	8.06 ± 2.99	10.19 ± 3.28	< 0.001

TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; APTT: Activated partial thromboplastin time; PT: Prothrombin time; FIB: Fibrinogen; CRP: C-reactive protein; PCT: Procalcitonin; WBC: White blood cell; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; UTI: Ulinastatin.